June 22 (Reuters) - The U.S. Food and Drug Administration on Thursday declined to grant accelerated approval for Intercept Pharmaceuticals' drug to treat a type of fatty liver disease.

(Reporting by Sriparna Roy, Leroy Leo and Raghav Mahobe in Bengaluru; Editing by Devika Syamnath and Shinjini Ganguli)